-
Amid calls of political favoritism, FDA continues to award national priority drug vouchers
In addition to questions from members of Congress, the program is facing scrutiny from medical organizations over whether it’s putting politics before science.
-
Injunction halts change to long-standing safety-net drug-pricing program
Under HHS’s rebate model program, safety-net providers would have to pay millions upfront for drugs that would otherwise be spent on low-income patients.
-
Third‑party disclosure: a practical guide for pharmaceutical compliance and risk teams
Principal third-party disclosure mechanisms and the common pitfalls for pharmaceutical compliance and risk teams.
-
A transformational 2025 in US healthcare – and more to come in 2026
In many ways, 2025 found the healthcare sector at a crossroads, with compliance officers holding their heads.
-
FDA turns focus on biologics in spate of warning letters
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.
-
CVS Health resolves $37.76m settlement with DOJ for over-dispensing insulin pens to patients
CVS admitted to dispensing more insulin to patients than needed and receiving ineligible reimbursements.
-
Fujifilm blazes a trail through pharma’s ethical quagmire
As advancements in research and drug development become more complex, bioethicists are helping companies find their footing along an increasingly ambiguous path.
-
IAPP EU Data Protection Congress 2025: Assessing Europe’s Health Data Space
An animated discussion on the theoretical benefits of the regulation and the gap between legislative dream and market reality.